XERS · Xeris Biopharma Holdings, Inc.
Market Cap
$1.52B
Shares
182.32M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$291.85M
+43.7%
FY2025
Net Income
$554K
+101%
FY2025
Operating Margin
8.53%
+25.1pp
FY2025
Diluted EPS
$0.00
+100%
FY2025
Operating Cash Flow
$28.63M
+177.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $335.41M | $291.85M | $203.07M | $163.91M | $110.25M | $49.59M | $20.44M | |
| $34.81M | $31.17M | $25.56M | $22.34M | $20.97M | $25.16M | $20.92M | |
| $208.14M | $182.37M | $163.48M | $146.1M | $137.75M | $125.72M | $73.73M | |
| $10.84M | $10.84M | $10.84M | $10.84M | $10.84M | $550K | $0 | |
| $1.33M | $1.31M | $1.23M | $1.49M | $1.4M | $1.33M | $1.47M | |
| $36.59M | $24.9M | -$33.65M | -$44.01M | -$81.94M | -$115.16M | -$83.55M | |
| — | 8.53% | -16.57% | -26.85% | -74.32% | -232.22% | -408.84% | |
| $37.93M | $26.21M | -$32.42M | -$42.52M | -$80.54M | -$113.83M | -$82.08M | |
| $28.25M | $29.08M | $30.49M | $26.61M | $14.1M | $7.18M | $10.66M | |
| -$53.76M | -$24.34M | -$23.46M | -$19.49M | -$14.14M | -$7.57M | -$7.7M | |
| — | $554K | -$57.1M | -$63.5M | -$96.08M | -$122.73M | — | |
| $0 | $0 | -$2.27M | -$1.25M | -$1.42M | $0 | -$110K | |
| -$17.17M | $554K | -$54.84M | -$62.26M | -$94.66M | -$122.73M | -$91.14M | |
| — | 0.19% | -27% | -37.98% | -85.86% | -247.48% | -446% | |
| — | $554K | -$54.84M | -$62.26M | — | — | — | |
| -$17.15M | $554K | -$54.84M | -$62.26M | -$94.65M | -$122.76M | -$91.18M | |
| USD/shares | -$0.10 | $0.00 | -$0.37 | -$0.45 | -$0.70 | -$1.55 | — |
| USD/shares | -$0.10 | $0.00 | -$0.37 | -$0.45 | -$0.70 | -$1.55 | — |
| shares | — | 160.43M | 146.77M | 137.67M | 135.63M | 79.03M | 42.64M |
| shares | — | 172.74M | 146.77M | 137.67M | 135.63M | 79.03M | 42.64M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
4.93×
Peer median 2.39×
EV/EBIT
45.18×
Peer median 17.67×
P/E (TTM)
—
Peer median 15.50×
Peer medians compare against the 45 similar-size Drug Manufacturers - Specialty & Generic companies (of 95 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Recorlev | $139,283,000 | $64,277,000 | $29,547,000 | $7,429,000 | $0 |
| Gvoke | $94,108,000 | $82,829,000 | $67,045,000 | $52,527,000 | $38,917,000 |
| Keveyis | $47,649,000 | $49,530,000 | $56,772,000 | $49,307,000 | $10,363,000 |
| Royalty Contract and Other Revenue | $8,842,000 | $6,434,000 | $10,550,000 | $985,000 | $310,000 |
| Product Other | $1,963,000 | $0 | $0 | — | — |
Key facts
CIK
1867096
CUSIP
98422E103
13F (30d)
198 filings
197 filers
Visit website
Investor relations